The FDA on January 15, 2021 approved ENHERTU® for adult patients with locally advanced or metastatic HER2-positive Gastric or GastroEsophageal (GEJ) adenocarcinoma who have received a prior Trastuzumab-based regimen. ENHERTU® is a product of Daiichi Sankyo Company.
Other Pages – Bottom Ad
Advertisement
Subscribe
